Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

@article{Ibebuogu2015BivalirudinVH,
  title={Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.},
  author={Uzoma Nwachukwu Ibebuogu and Oluwaseyi Bolorunduro and Smith Giri and Samuel Dagogo-Jack and Blake G Smith and Saibal Kar and Guy L Reed},
  journal={American journal of cardiovascular drugs : drugs, devices, and other interventions},
  year={2015},
  volume={15 4},
  pages={275-85}
}
Diabetes mellitus (DM) is a pro-thrombotic state with enhanced thrombin generation and platelet reactivity. For most patients undergoing percutaneous coronary intervention (PCI), bivalirudin demonstrates efficacy comparable with that of heparin and glycoprotein IIb/IIIa inhibitors (GPIs). Yet, because of their pro-thrombotic condition, we hypothesized that patients with DM may benefit from more aggressive dual antithrombin and antiplatelet therapy. The aim of this paper was to provide a… CONTINUE READING